Pharmaceutical

EC approves Alnylam’s vutrisiran for ATTR-CM treatment

The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

Jun 11, 2025 - 06:00
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.
Read the original article

Tags:

Previous Article

MSD receives FDA approval for Enflonsia to prevent RSV

Next Article

FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Current large language models will not fix health care. Here’s what could

Opinion: Current large language models will not fix hea...

Aug 25, 2023

With arrival of breakthrough therapies, a rare disease group reconsiders the possible — and its mission

With arrival of breakthrough therapies, a rare disease ...

Mar 28, 2023

STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

STAT+: Colombia set to issue a compulsory license for a...

Oct 4, 2023